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ABSTRACT
BACKGROUND Financial toxicity (FT) is a well-established side-effect of the high costs associated with cancer care. In
recent years, studies have suggested that a significant proportion of those with atherosclerotic cardiovascular disease
(ASCVD) experience FT and its consequences.
OBJECTIVES This study aimed to compare FT for individuals with neither ASCVD nor cancer, ASCVD only, cancer only,
and both ASCVD and cancer.
METHODS From the National Health Interview Survey, we identified adults with self-reported ASCVD and/or cancer
between 2013 and 2018, stratifying results by nonelderly (age <65 years) and elderly (age $65 years). We defined FT if
any of the following were present: any difficulty paying medical bills, high financial distress, cost-related medication
nonadherence, food insecurity, and/or foregone/delayed care due to cost.
RESULTS The prevalence of FT was higher among those with ASCVD when compared with cancer (54% vs. 41%; p <
0.001). When studying the individual components of FT, in adjusted analyses, those with ASCVD had higher odds of any
difficulty paying medical bills (odds ratio [OR]: 1.22; 95% confidence interval [CI]: 1.09 to 1.36), inability to pay bills (OR:
1.25; 95% CI: 1.04 to 1.50), cost-related medication nonadherence (OR: 1.28; 95% CI: 1.08 to 1.51), food insecurity (OR:
1.39; 95% CI: 1.17 to 1.64), and foregone/delayed care due to cost (OR: 1.17; 95% CI: 1.01 to 1.36). The presence of $3 of
these factors was significantly higher among thosewith ASCVD and thosewith both ASCVD and cancerwhen comparedwith
those with cancer (23% vs. 30%vs. 13%, respectively; p<0.001). These results remained similar in the elderly population.
CONCLUSIONS Our study highlights that FT is greater among patients with ASCVD compared with those with
cancer, with the highest burden among those with both conditions. (J Am Coll Cardiol CardioOnc 2021;3:236–46)
© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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F inancial toxicity (FT) refers to the financialstrain that patients experience while accessinghealth care, and has been widely researched in
cancer patients (1). Used interchangeably with “finan-
cial hardship,” “financial (di)stress,” “(high) financial
burden,” “economic burden,” and “economic hard-
ship” (2), it has been reported that a large proportion
of patients with cancer experience FT (3–5). This
affliction is not limited to cancer diagnosis, but also
manifests as the impaired health of patients following
treatment and survivorship (6). These insights have
also been directed toward implementation of FT-
specific interventions for better screening, social sup-
port, and care for patients with cancer (7–10).
Although there has been an emphasis on under-
standing and remedying FT in patients with cancer
(3), this phenomenon has been studied less
frequently among patients with atherosclerotic car-
diovascular disease (ASCVD). The extent of FT and
how it manifests might differ between patients with
ASCVD and cancer. For example, patients with cancer
may have short bursts of high expenditures with
chemotherapy, whereas ASCVD incurs a more chronic
economic burden related to the costs of drugs, pro-
cedures, clinician visits, and hospital stays (11). The
economic burden that ASCVD confers to patients and
families who experience it has been described in the
last few years (12–15). Additionally, with prolonged
survival following the diagnosis of cancer, the cardiac
toxicity of some treatments, and better treatment
options for ASCVD, the population of patients with
simultaneous ASCVD and cancer is growing. Without
the ability to pay, patients can experience financial
health and non–health-related difficulties, such as
difficulty paying medical bills, financial distress, cost-
related medication nonadherence, and food insecu-
rity, and may forego or delay care due to cost (16–19).
However, no studies to date have contrasted the FT
incurred in patients with ASCVD and/or cancer, which
are currently the 2 leading causes of death in the
United States (20). The current study, using a na-
tionally representative sample of the United States,
compared the financial burden of health care on adult
patients with neither ASCVD nor cancer, ASCVD only,
cancer only, and both ASCVD and cancer.
METHODS
STUDY DESIGN. We utilized 6 years of data
(2013 to 2018) from the NHIS (National Health
Interview Survey). The NHIS, a database
compiled by the National Center for Health
Statistics/Center for Disease Control and
Prevention, is constructed from annual,
cross-sectional national surveys that incor-
porate complex, multistage sampling to pro-
vide estimates on the noninstitutionalized
U.S. population (21). The NHIS questionnaire
is divided into 4 core components: House-
hold Composition, Family Core, Sample Child
Core, and Sample Adult Core (21). The Household
Composition file collects basic information and rela-
tionship information about all persons in a house-
hold. The Family Core file collects sociodemographic
characteristics, basic indicators of health status, ac-
tivity limitations, injuries, health insurance coverage,
and access to, and utilization of, health care services.
From each family, 1 sample child and 1 sample adult
are randomly selected to gather more detailed infor-
mation. This study utilized the Sample Adult Core
files (with relevant variables added from the Family
Core files), which are supplemented with de-
mographic and socioeconomic characteristics, health
status, health care services, and health-related be-
haviors on the U.S. adult population (21). Because
NHIS data are publicly available and deidentified, this
study was exempt from institutional review board
approval (22).
STUDY POPULATION. We used a self-reported diag-
nosis of coronary or cerebrovascular disease to iden-
tify patients with ASCVD. Specifically, individuals
were included if they reported having coronary artery
disease (“yes” to any of the following 3 questions:
“Have you ever been told by a doctor or other health
professional that you had.coronary heart disease,”
“.angina, also called angina pectoris,” or “.a heart
attack [also called myocardial infarction]?”) and/or
stroke (“yes” to the following question: “Have you
ever been told by a doctor or other health professional
that you had a stroke?”) were classified as having




BMI = body mass index
CI = confidence interval
COST = Comprehensive Score
for Financial Toxicity
CRF = cardiovascular risk
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ASCVD. Similarly, individuals that answered “yes” to
the question, “Have you ever been told by a doctor or
other health professional that you had cancer or a
malignancy of any kind?” were classified as having
cancer. These methods of diagnosis ascertainment
have been used in previous literature (12,23). For our
main analyses, we included only non-elderly ($18
to <65 years of age) adults to capture the population
without universal financial protections from public
insurance. As a subanalysis, we further extended our
study population to elderly ($65 years of age) adults.
STUDY OUTCOMES. F inanc ia l tox ic i ty . For the
purposes of this paper, we defined FT as having any
of the following: difficulty paying medical bills,
inability to pay them at all, high financial distress,
cost-related medication nonadherence, food
insecurity, and/or delayed/foregone care due to
cost. The specific questions and definitions for each
FT component are presented in Supplemental Table 1.
Difficu l ty pay ing med ica l b i l l s . The following
questions were used to assess the study population
having “any difficulty paying medical bills”:
 “In the past 12 months, did you/anyone in your
family have problems paying or were unable to pay
any medical bills? Include bills for doctors, dentists,
hospitals, therapists, medication, equipment,
nursing home or home care,” or
 “Do you/anyone in your family currently have any
medical bills that are being paid off over time? This
could include medical bills being paid off with a
credit card, through personal loans, or bill paying
arrangements with hospitals or other providers. The
bills can be from earlier years as well as this year.”
This approach has been previously employed in
other studies and surveys (24,25). Additionally, for
individuals who answered “yes” to having difficulty
paying bills, a follow-up question was asked: “Do you/
does anyone in your family currently have any medical
bills that you are unable to pay at all?” Individuals
who answered “yes” to this question were studied as
a separate group—those who were “unable to pay bills
at all.”
High financ ia l d i st ress . Financial distress was
derived from 6 questions regarding the level of
concern with several financial matters, including:
lack of retirement funds, ability to pay medical costs
of serious illness, maintaining an acceptable quality
of living, ability to pay day-to-day health care costs,
inability to pay monthly bills, and inability to pay
rent/mortgage/housing costs (Supplemental Table 1).
The questions were responded to on a 4-point scale,
ranging from “not worried at all” to “very worried.”
An aggregate score was created, ranging from 6 to 24,
a higher score indicating increased levels of financial
distress (26). Participants within the highest quartile
were designated as experiencing high levels of
financial distress.
Cost- re lated medicat ion nonadherence . Cost-
related medication nonadherence was defined as a
survey responder reporting any of the following be-
haviors to save money in the last 12 months: skipping
medication doses, taking less medicine, or delaying
filling a prescription (Supplemental Table 1).
Food insecur i ty . Food security in the last 30 days
was created based on the 10-item questionnaire as
recommended by the U.S. Department of Agriculture
Economic Research Service (Supplemental Table 1)
(27,28), and constructed per the NHIS instructions
(28). In questions about frequency of occurrence in
the past 30 days, answers of $ 3 days were considered
affirmative. A raw score ranging from 0 to 10 was
calculated, with the following categories: food secure
(score 0 to 2), low food security (score 3 to 5), and very
low food security (score 6 to 10). For this study’s
purposes, food insecurity included those who had
either low or very low food security, as is common in
practice (29).
Delayed/foregone care due to cost . Delayed
and/or foregone care due to cost was assessed by
asking individuals whether, within the past year,
medical care had been delayed due to cost, or if they
needed but did not receive medical care due to cost
(30).
COVARIATES. Other covariates included in this
study were age, sex, race/ethnicity, family income,
education, insurance status, region, cardiovascular
risk factor (CRF) profile, number of chronic comor-
bidities, and for individuals with cancer, years since
diagnosis. Categorical variables were classified as
follows: 2 categories for sex; 3 categories for race/
ethnicity (non-Hispanic White, non-Hispanic Black,
and Hispanic); 2 categories for family income (based
on percent of family income to the federal poverty
limit from the Census Bureau: high/middle-income
[$200%], low-income [<200%]); 2 categories for ed-
ucation (some college or higher, high school/GED or
less than high school); 2 categories for insurance
status (insured, uninsured), and 4 categories for
geographic region (Northeast, Midwest, South, and
West). CRF profile was calculated by determining, via
self-report, whether individuals had 1 or more of the
following: diagnosis of hypertension, diabetes melli-
tus or high cholesterol, obesity (calculated body mass
index $30 kg/m2), current smoker, or insufficient
physical activity (based on not participating in >150
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min/week of moderate-intensity aerobic physical ac-
tivity, >75 min/week of vigorous-intensity aerobic
physical activity, or a total combination of $150 min/
week of moderate/vigorous-intensity aerobic physical
activity). Based on the presence of these individual
risk factors, individuals were categorized as “poor”
($4 CRFs), “average” (2 to 3 CRFs), and “optimal” (0
to 1 CRF) (31,32). Self-reported chronic comorbidities,
including emphysema, chronic obstructive pulmo-
nary disease, asthma, gastrointestinal ulcer, arthritis
(including arthritis, gout, fibromyalgia, rheumatoid
arthritis, and systemic lupus erythematosus), any
kind of liver condition, or “weak/failing” kidneys,
were aggregated, and categorized as having 0, 1,
or $2. For individuals with cancer, time since diag-
nosis was measured in years, and presented as both
continuous, and categorized as $0 to #5, >5 to #15,
and >15 years.
STATISTICAL ANALYSIS. Chi-square tests were used
to compare categorical variables, and weighted pro-
portions were used to study prevalence. Continuous
variables were reported as medians with interquartile
range. Categorical variables were reported as un-
weighted counts with their accompanying weighted
proportions (in tables), and as weighted proportions
with 95% confidence interval (CI) (in figures).
Further, we used linear regression to test for linear
trends of the prevalence of FT measures between
disease groups. Unadjusted and adjusted logistic
regression models were used to measure the associ-
ation between FT prevalence and disease group
(neither ASCVD nor cancer, ASCVD, cancer, or both
ASCVD and cancer), and were reported as odds ratios
(ORs) with 95% CIs. Adjusted models included vari-
ables that have been correlated with presence and/or
risk for FT (e.g., income and insurance status), or that
are clinically significant (e.g., age, cardiovascular risk
factors, and comorbidities). We used the Akaike In-
formation Criterion to determine the optimal vari-
ables to include in our adjusted model. The full list of
explanatory variables included age, sex, race/
ethnicity, family income, education, insurance sta-
tus, geographic region, cardiovascular risk factor
profile, and comorbidities for all outcome measures;
in the case of high financial distress, cost-related
medication nonadherence, food insecurity, and fore-
gone/delayed care due to cost, burden from medical
bills was also included due to the risk of confounding.
Similar models were constructed for the individual
components of FT. Variance estimation for the entire
pooled cohort was obtained from the Integrated
Public Use Microdata Series (33). For all statistical
analyses, p < 0.05 was considered statistically sig-
nificant. All analyses were carried out using Stata
version 16 (StataCorp, LP, College Station, Texas). All
analyses were survey-specific considering the com-
plex design of the NHIS survey.
RESULTS
NON-ELDERLY POPULATION. From 2013 to 2018, the
NHIS total sample of non-elderly ($18 to <65 years of
age) adults was 141,826, of which 6,887 (weighted
prevalence: 4.5% [95% CI: 4.4% to 4.7%]), 6,093
(weighted prevalence: 3.8% [95% CI: 3.7% to 4.0%]),
and 971 (weighted prevalence: 0.6% [95% CI: 0.56% to
0.65%]) had cancer, ASCVD, and both ASCVD and
cancer, respectively. This translates to 8.9, 7.5, and
1.2 million non-elderly U.S. adults yearly, respec-
tively (Table 1).
Most individuals in the non-elderly population
were 40 to 64 years of age, insured, and White.
Women were more likely to report having cancer,
with a majority coming from middle-/high-income
households and with a higher education level. In
contrast, those reporting ASCVD (with or without
cancer) were evenly distributed by sex, education,
and income levels, although with a shift toward a
more unfavorable CRF profile (Table 1). Among the
non-elderly adults with cancer, the most frequently
reported cancers included skin (nonmelanoma),
breast, cervix, prostate, and “other” (Supplemental
Table 2). Similar patterns were observed in the pop-
ulation that reported both ASCVD and cancer.
Prevalence of FT measures by underlying condi-
tion are comprehensively depicted in our Central
Illustration. Any FT was present to a higher extent
across disease categories from neither ASCVD nor
cancer (38.3% [95% CI: 37.8% to 38.9%]), to cancer
(41.0% [95% CI: 39.5% to 42.6%]), to ASCVD (54.1%
[95% CI: 52.4% to 55.8%]), and both (ASCVD and
cancer; 54.5% [95% CI: 50.3% to 58.7%]) (p
trend <0.001) (Central Illustration). Difficulty paying
medical bills was significantly higher for individuals
with ASCVD (with or without cancer; 44.8% [95% CI:
43.1% to 46.5%] and 47.4% [95% CI: 43.1% to 51.7%],
respectively) when compared with those with cancer
(35.0% [95% CI: 33.5% to 36.6%]). When analyzing
those with the highest burden from medical bills—
those with an inability to pay bills at all—a statistically
significant trend was also seen when comparing
cancer (10.1% [95% CI: 9.0% to 11.3%]) versus ASCVD
(18.2% [95% CI: 16.9% to 19.5%]) versus both (23.2%
[95% CI: 19.8% to 26.8%]) (p trend <0.001). Overall,
the same pattern (i.e., ASCVD and cancer > ASCVD >
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cancer > neither) was observed for high financial
distress, cost-related medication nonadherence, food
insecurity, and delayed/foregone medical care due to
cost when comparing those reporting ASCVD (with or
without cancer) versus cancer (all p trend <0.001).
In univariable logistic regression analysis, patients
with both cancer and ASCVD had increased odds of
any FT (OR: 1.93; 95% CI: 1.63 to 2.28). This was
further observed in all of FT measures: any difficulty
paying medical bills (OR: 2.27; 95% CI: 1.91 to 2.70),
inability to pay medical bills at all (OR: 3.43; 95% CI:
2.83 to 4.16), high financial distress (OR: 2.46; 95% CI:
2.08 to 2.92), cost-related medication nonadherence
(OR: 4.72; 95% CI: 3.86 to 5.78), food insecurity (OR:
3.19; 95% CI: 2.65 to 3.83), and foregone/delayed care
due to cost (OR: 2.51; 95% CI: 2.08 to 3.03) when
compared with patients who reported neither disease
(Table 2). The presence of ASCVD with or without
cancer was associated with an increased odds for all
FT measures when compared with individuals with
cancer, as evidenced by nonoverlapping CIs. In
multivariable analysis, after adjusting for con-
founders including variables such as family income
and insurance status, the effect sizes were attenuated
but associations remained consistent and statistically
significant: those with ASCVD and cancer had
increased odds of being unable to pay medical bills at
all, high financial distress, cost-related medication
nonadherence, and foregone/delayed medical care,
when compared with those with cancer (Table 2). Of
note, even though effect sizes were larger (i.e., higher
ORs), there were no statistical differences between
the groups with ASCVD only and both ASCVD and
cancer in adjusted analyses (interaction p ¼ 0.39). Our
findings further reinforce the notion that presence of
ASCVD was a key determinant of the presence and
severity of FT.
Furthermore, in a composite score of number of
FT measures each individual had, we found that the
prevalence of having $3 was 9% (z17.2 million)
among those with neither disease, 13%
(z25.3 million) among those with cancer, 23%
(z44.5 million) among those with ASCVD, and 30%
(z57.9 million) among those with both (p
trend <0.001) (Figure 1).
ELDERLY POPULATION. From 2013 to 2018, the NHIS
total sample of elderly ($65 years of age) adults was
48,287, of which 8,457 (weighted prevalence: 18.1%
[95% CI: 17.7% to 18.6%]), 8,167 (weighted preva-
lence: 16.9% [95% CI: 16.4% to 17.3%]), and 3,211
(weighted prevalence: 6.8% [95% CI: 6.5% to 7.1%])
had cancer, ASCVD, and both, respectively. This
translates to 8.6, 8.0, and 3.2 million elderly U.S.
adults yearly (Supplemental Table 3). Virtually all
patients in this age category were White and insured,
and the majority were from middle/high-income
households. Individuals with ASCVD (regardless of
cancer diagnosis) were more likely to be men,
whereas older adults (age $75 years) were more likely
to have combined ASCVD and cancer diagnoses.
Among the elderly adults with cancer, the most
TABLE 1 General Characteristics Among Non-Elderly Adults With Cancer and/or ASCVD,



















18–39 61,680 (50.7) 979 (14.3) 717 (13.3) 66 (7.8)
40–64 66,195 (49.3) 5,908 (85.7) 5,376 (86.7) 905 (92.2)
Sex
Male 59,431 (49.3) 2,350 (36.2) 3,390 (59.1) 441 (48.7)
Female 68,444 (50.7) 4,537 (63.8) 2,703 (40.9) 530 (51.3)
Race/ethnicity
Non-Hispanic White 78,011 (61.7) 5,626 (83.6) 3,801 (64.9) 762 (82.1)
Non-Hispanic Black 17,463 (13.2) 503 (6.4) 1,146 (17.1) 105 (9.3)
Non-Hispanic Asian 8,184 (6.6) 155 (2.5) 177 (3.3) 6 (0.5)
Hispanic 22,416 (18.4) 526 (7.5) 838 (14.8) 72 (8.1)
Family income
Middle/high income 77,946 (69.5) 4,658 (77.9) 2,724 (54.1) 424 (54.3)
Low income 42,332 (30.5) 1,826 (22.1) 3,059 (45.9) 497 (45.7)
Education
Some college or higher 82,769 (64.6) 4,777 (70.4) 2,993 (50.2) 543 (56.8)
HS/GED or less than HS 44,652 (35.4) 2,094 (29.6) 3,076 (49.8) 425 (43.2)
Insurance status
Insured 107,418 (85.3) 6,327 (92.9) 5,335 (87.9) 887 (91.7)
Uninsured 19,816 (14.7) 544 (7.1) 740 (12.1) 79 (8.3)
Region
Northeast 20,323 (17.4) 1,120 (17.3) 894 (15.1) 141 (15.8)
Midwest 27,750 (22.2) 1,602 (23.6) 1,344 (23.6) 213 (24.1)
South 45,443 (36.3) 2,379 (37.2) 2,566 (42.7) 415 (43.0)
West 34,359 (24.0) 1,786 (22.0) 1,289 (18.6) 202 (17.0)
CRF profile
Optimal 73,456 (61.2) 2,952 (47.4) 940 (17.9) 142 (16.5)
Average 41,420 (32.8) 2,789 (41.2) 2,637 (45.6) 390 (45.2)
Poor 8,187 (6.0) 819 (11.3) 2,131 (36.4) 360 (38.3)
Comorbidities
0 88,643 (70.8) 3,203 (48.3) 2,149 (37.9) 210 (25.0)
1 29,926 (22.7) 2,259 (32.8) 1,950 (32.5) 270 (28.6)
$2 9,306 (6.5) 1,425 (18.9) 1,994 (29.6) 491 (46.4)
Years since cancer diagnosis — 6 (2–14) — 7 (2–16)
Years since cancer diagnosis
0 to #5 — 2,989 (44.7) — 400 (41.6)
>5 to #15 — 2,336 (33.8) — 287 (31.6)
>15 — 1,562 (21.5) — 284 (26.8)
Values are n, n (%), or median (interquartile range). All p values for comparison between groups were <0.001.
ASCVD ¼ atherosclerotic cardiovascular disease; CRF ¼ cardiovascular risk factor; GED ¼ general equivalency
diploma; HS ¼ high school.
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CENTRAL ILLUSTRATION Prevalence of Financial Toxicity Measures by Cancer and/or ASCVD
Status, Among Non-Elderly Adults, From the National Health Interview Survey, 2013 to 2018
Valero-Elizondo, J. et al. J Am Coll Cardiol CardioOnc. 2021;3(2):236–46.
Any financial toxicity: any difficulty paying medical bills  unable to pay bills at all  high financial distress  cost-related medication non-
adherence  food insecurity  delayed/foregone care due to cost. The p value for linear trends was <0.001 for all financial toxicity
prevalence measures when comparing disease groups. Data in this figure represents weighted prevalence (bars) with 95% confidence interval
(error bars). ASCVD ¼ atherosclerotic cardiovascular disease; NHIS ¼ National Health Interview Survey.
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frequently reported cancers included breast, prostate,
and skin (unknown kind). Similar patterns were
observed in the population that reported both ASCVD
and cancer (Supplemental Table 2).
Prevalence of FT measures by underlying condi-
tion among elderly adults are described in
Supplemental Figure 1. Overall, the same pattern was
observed for all FT measures as seen with non-elderly
adults, although at significantly lower proportions.
Individuals reporting ASCVD with or without cancer
had a higher degree of difficulty paying medical bills,
inability to pay at all, high financial distress, cost-
related medication nonadherence, food insecurity,
and delayed/foregone medical care due to cost
(Supplemental Figure 1). After adjusting for estab-
lished confounders, presence of ASCVD was associ-
ated with a significantly higher odds of any difficulty
paying medical bills and being unable of paying them
at all when compared with those without ASCVD or
cancer (Supplemental Table 4).
SENSITIVITY ANALYSES. Given the high prevalence
of nonmelanomatous skin cancer, we performed
similar analyses excluding this diagnosis. In
addition, we also performed analyses including
breast, lung, and colorectal cancer only within our
cancer group (i.e., no other cancer diagnoses were
included), given their high incidence and mortality.
Moreover, given concerns of having varying lengths
of time and survival for different cancers and in-
dividuals, we performed 2 additional analyses: first,
a comparison including only those with an active
cancer diagnosis (i.e., only those with a cancer
diagnosis diagnosed within the past year were
included); and second, a series of stratified analyses
by time since cancer diagnosis ($0 to #5, >5 to #15,
and >15 years). Overall, the patterns for FT mea-
sures remained similar in magnitude and direction
among both non-elderly and elderly adults when
comparing cancer and/or ASCVD (Supplemental
Figures 2 to 13).
DISCUSSION
In a nationally representative study using data from
2013 to 2018, we found that among non-elderly
adults, ASCVD was associated with higher
TABLE 2 Burden of Financial Toxicity Among Non-Elderly Adults With and Without Cancer and/or ASCVD, From the National Health
Interview Survey, 2013 to 2018




Model 1 Reference 1.12 (1.05–1.20) 1.90 (1.77–2.03) 1.93 (1.63–2.28)
Model 2 1.12 (1.04–1.21) 1.35 (1.25–1.47) 1.39 (1.14–1.69)
Any difficulty paying medical bills
Model 1 Reference 1.36 (1.27–1.45) 2.04 (1.91–2.19) 2.27 (1.91–2.70)
Model 2 1.29 (1.20–1.39) 1.53 (1.41–1.65) 1.54 (1.27–1.86)
Unable to pay medical bills
Model 1 Reference 1.27 (1.12–1.45) 2.52 (2.30–2.76) 3.43 (2.83–4.16)
Model 2 1.29 (1.11–1.50) 1.54 (1.38–1.71) 2.02 (1.59–2.57)
High financial distress
Model 1 Reference 1.15 (1.07–1.24) 2.04 (1.90–2.18) 2.46 (2.08–2.92)
Model 2 1.03 (0.95–1.12) 1.13 (1.04–1.24) 1.26 (1.03–1.55)
Cost-related medication nonadherence
Model 1 Reference 1.78 (1.62–1.96) 3.22 (2.93–3.54) 4.72 (3.86–5.78)
Model 2 1.17 (1.04–1.31) 1.48 (1.32–1.67) 1.63 (1.27–2.09)
Food insecurity
Model 1 Reference 0.95 (0.86–1.05) 2.65 (2.45–2.87) 3.19 (2.65–3.83)
Model 2 0.95 (0.84–1.07) 1.27 (1.14–1.42) 1.34 (1.05–1.69)
Foregone/delayed care due to cost
Model 1 Reference 1.33 (1.21–1.45) 2.08 (1.92–2.25) 2.51 (2.08–3.03)
Model 2 1.14 (1.02–1.26) 1.32 (1.18–1.47) 1.61 (1.28–2.03)
Values are odds ratio (95% confidence interval). *Any difficulty paying medical bills  high financial distress  cost-related medication non-adherence  food insecurity 
delayed/foregone care due to cost. Model 1: unadjusted. Model 2: adjusted for age, sex, race/ethnicity, family income, education, insurance type, geographic region, car-
diovascular risk factor profile, comorbidities, and, where appropriate (high financial distress, cost-related medication nonadherence, food insecurity and foregone/delayed care
due to cost), burden from medical bills.
Abbreviations as in Table 1.
Valero-Elizondo et al. J A C C : C A R D I O O N C O L O G Y , V O L . 3 , N O . 2 , 2 0 2 1
Financial Toxicity Among ASCVD/Cancer J U N E 2 0 2 1 : 2 3 6 – 4 6
242
proportions of overall FT than patients with cancer,
and patients with both illnesses concurrently had the
worst outcomes across different measures of FT.
These results were observed among elderly adults as
well, although at significantly lower proportions.
These findings demonstrate the severity of FT in pa-
tients with ASCVD when compared with cancer, the
latter being one of the most researched causes of FT
in the current published medical literature (3,4,7).
Our findings extend the prior published literature
in several ways. First, to our knowledge, this is the
first study directly analyzing FT in patients with
cancer versus patients with ASCVD. Prior studies have
suggested that the effect of ASCVD on FT is likely
equivalent to or greater than that of cancer, but this
issue had not been definitively investigated (34,35).
In a previous paper, Narang et al. (34) detailed the
differences in Medicare beneficiaries with cancer
(compared with those without cancer, and sub-
stratified by other comorbidities), their out-of-pocket
(OOP) expenditures, and financial burden. They
showed that individuals with heart disease and/or
stroke had higher median OOP expenditures ($2,371
vs. $2,120; p < 0.05) and financial burden (7.0% vs.
5.7%; p < 0.05) when compared with those with
cancer in the overall study population. Our results
not only confirm that individuals with a diagnosis of
cancer have higher odds of all measures of FT than
those without cancer nor ASCVD, but also highlight
the burden that ASCVD represents in the overall adult
population. Second, our study highlights the degree
to which patients with these diseases experience
financial health-related consequences. Furthermore,
we also broaden the scope of the FT phenomenon
across all adults, non-elderly and elderly. Our main
study population was non-elderly adults, given that
this population tends to have higher FT overall (5).
Interestingly, we found that ASCVD was associated
with a higher prevalence of FT, both alone and when
occurring concurrently with cancer, compared with
patients with cancer, including the elderly popula-
tion. Based on previous reports, the drivers of FT,
however, may be different in these populations; FT in
cancer usually stems from cancer therapy pharma-
ceutical pricing (36), whereas ASCVD tends to be
related to acute events often requiring hospitaliza-
tion, like myocardial infarctions and/or stroke (13).
FT in cancer has been well described (3,5). Our
results align with previous studies that found in-
dividuals with cancer to have high financial distress,
cost-related medication nonadherence, food insecu-
rity, and foregone/delayed care overall (10,23,37).
Although understudied, our results build on the cur-
rent published data regarding individuals with
ASCVD as also having a high degree of the ill-
associated measures under the umbrella of FT
(12,13,35).
Our findings highlight the prevalence of, and ur-
gent need for, effective methods to alleviate FT for
ASCVD and cancer patients. In the current health
system climate, there are small- and large-scale
strategies to identify and combat FT. Clinicians can
help patients deal with FT, as observed among on-
cologists when prompted to talk to their patients
about financial burden in the office (38). This may be
especially important for physicians, nurses, and
advanced practice providers who care for patients
with ASCVD and/or cancer, given the high economic
burden and morbimortality potential these diseases
carry. Indeed, it has been reported that a majority of
patients with FT-related issues would like to discuss
this problem with their health care providers; how-
ever, reports indicate that discussions addressing
these concerns happen approximately in one-third of
encounters (39) and are often not addressed at all
(40–42). There are tools available for clinicians to
address this problem. One such validated tool to
engage with patients and test for FT is the COmpre-
hensive Score for financial Toxicity (COST), a patient-
reported outcome measure to gauge FT in patients
FIGURE 1 Distribution of Total Burden From Financial Toxicity Measures, by ASCVD
and/or Cancer Status, Among Non-Elderly Adults, From the National Health
Interview Survey, 2013 to 2018
FT measures: any difficulty paying medical bills  high financial distress  cost-related
medication non-adherence  food insecurity  delayed/foregone care due to cost.
ASCVD ¼ atherosclerotic cardiovascular disease; FT ¼ financial toxicity; NHIS ¼ National
Health Interview Survey.
J A C C : C A R D I O O N C O L O G Y , V O L . 3 , N O . 2 , 2 0 2 1 Valero-Elizondo et al.
J U N E 2 0 2 1 : 2 3 6 – 4 6 Financial Toxicity Among ASCVD/Cancer
243
with cancer, which has been validated in the United
States and abroad (43–45). However, to our knowl-
edge, there are currently no tools for clinicians to
measure FT among patients with ASCVD. Given the
promise shown by COST, future work should develop
and validate tools similar to COST for ASCVD pa-
tients. Such assessments leveraged proactively (e.g.,
during annual check-ups) combined with patient
education on the costs involved in treatment of
chronic cardiovascular conditions may persuade pa-
tients to adopt healthier lifestyles that effectively
avoid potential FT. For this reason, the American
Heart Association and the American College of Car-
diology will likely incorporate value and cost in their
next guidelines (46). However, as a strong research
field in medications, devices, and innovation, cardi-
ology clinicians are lagging behind in terms of FT in
an era where treatment permits longer survival for
their patients. This is paramount due to patients with
cancer and/or ASCVD living longer lives through
better and earlier care—which in parallel increases
the potential for FT. Even with an aging population,
which by definition has higher risk for both diseases
and access to universal health coverage, Medicare
patients appear to have lower FT, but are still not
exempt from it (34,47); this population would ulti-
mately have to deal with problems of a different na-
ture altogether, like caregiver distress and end-of-life
care and costs. We hope that by describing the extent
of FT in patients with ASCVD, cancer, or both, clini-
cians will not only be able to provide better care, but
will also be able develop support structures and in-
terventions for the patients experiencing these dis-
eases and FT (48).
STUDY LIMITATIONS. First, our study population—
those with ASCVD and/or cancer—was based on self-
report. Although self-reported conditions can be
potentially inaccurate, our estimates agree with
those from previous published data using NHIS
(12,49,50), and are in line with those reported by
national associations, like the American Heart Asso-
ciation and the Centers for Disease Control and
Prevention (51,52). Second, we evaluate a limited
number of features of FT from health care. Other
aspects of financial ill-effects of treatments may not
be captured. However, our focus was on domains
that have been validated and widely used in prior
studies and have shown to correlate well with
objective measures of financial burden from OOP
costs for medical expenditures (53). Third, questions
relating to financial hardship used in NHIS assessed
not only whether an individual but also whether
anyone in the household had financial hardship, and
precludes assessment of the proportion of medical
bills directly related to ASCVD and/or cancer and
their contribution to financial hardship itself. Khera
et al. (13) recently detailed that health care spending
on family members with ASCVD represented a mean
of 70% of the overall family OOP health spending,
with the respective proportion being slightly higher
for low-income families. Fourth, it was not possible
to differentiate the proportion of financial hardship
caused by a specific catastrophic event from the ef-
fect of chronic bills. A recent survey suggested that
over 60% of individuals with financial hardship from
medical bills reported it being tied to a catastrophic
medical expense, whereas 1 reports bills for treat-
ment of chronic conditions that have built up over
time (54). Fifth, it is difficult to establish causality
due to the cross-sectional nature of this study. It is
possible that there is a bidirectional relationship
between FT and some of its perceived effects on
ASCVD and/or cancer. For example, it has been
described that food insecurity is often more preva-
lent in the low-income population (55–57), hinting
toward an income-based problem rather than a
purely health-related financial consequence.
Although is it plausible that causality may be bidi-
rectional (i.e., food insecurity could lead to inade-
quate financial coping behaviors, or financial
hardship could lead to food insecurity) (57), others
have argued that health behaviors could potentially
be affected by food insecurity (58). Sixth, no ad-
justments for possible type 1 errors for multiple
comparisons were used, so these results should be
interpreted with caution. Finally, there is a possi-
bility that the strategies to mitigate FT in cancer
have started yielding positive results, and these are
reflected in our analyses.
CONCLUSIONS
Patients with ASCVD report greater difficulty paying
bills and experience high financial distress from
medical costs, cost-related medication non-
adherence, and food insecurity, and they forego/
delay care due to cost at a proportion exceeding those
with the population with cancer. It is critical that
interventions to mitigate treatment-related costs that
have been implemented among cancer patients are
evaluated for patients with ASCVD. Finally, we hope
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that the findings documented here would serve as
the basis for future prospective patient-centered in-
quiries to investigate patients’ perceptions of FT
to inform well-accepted and sustainable
interventions.
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